Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

The identification of CCL18 as biomarker of disease activity in localized scleroderma.

Mertens JS, de Jong EMGJ, van den Hoogen LL, Wienke J, Thurlings RM, Seyger MMB, Hoppenreijs EPAH, Wijngaarde CA, van Vlijmen-Willems IMJJ, van den Bogaard E, Giovannone B, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD.

J Autoimmun. 2019 Jul;101:86-93. doi: 10.1016/j.jaut.2019.04.008. Epub 2019 Apr 18.

PMID:
31006523
2.

Driving Medical Innovation Through Interdisciplinarity: Unique Opportunities and Challenges.

Gohar F, Maschmeyer P, Mfarrej B, Lemaire M, Wedderburn LR, Roncarolo MG, van Royen-Kerkhof A.

Front Med (Lausanne). 2019 Feb 26;6:35. doi: 10.3389/fmed.2019.00035. eCollection 2019. No abstract available.

3.

Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.

Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, Yeo JG, Meyer A, Otten HG, Fritsch-Stork RDE, Kamphuis SSM, Hoppenreijs EPAH, Armbrust W, van den Berg JM, Hissink Muller PCE, Tekstra J, Hoogendijk JE, Deakin CT, de Jager W, van Roon JAG, van der Pol WL, Nistala K, Pilkington C, de Visser M, Arkachaisri T, Radstake TRDJ, van der Kooi AJ, Nierkens S, Wedderburn LR, van Royen-Kerkhof A, van Wijk F.

Arthritis Rheumatol. 2019 Aug;71(8):1377-1390. doi: 10.1002/art.40881. Epub 2019 Mar 12.

PMID:
30861625
4.

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ.

Arthritis Rheumatol. 2019 Jul;71(7):1163-1173. doi: 10.1002/art.40865. Epub 2019 May 25.

5.

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A.

Front Immunol. 2018 Dec 18;9:2951. doi: 10.3389/fimmu.2018.02951. eCollection 2018. Review.

6.

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative.

de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Brogan P, Beresford MW.

Rheumatology (Oxford). 2019 Apr 1;58(4):672-682. doi: 10.1093/rheumatology/key344.

PMID:
30535127
7.

Non-pharmacological options for managing chronic musculoskeletal pain in children with pediatric rheumatic disease: a systematic review.

Nijhof LN, Nap-van der Vlist MM, van de Putte EM, van Royen-Kerkhof A, Nijhof SL.

Rheumatol Int. 2018 Nov;38(11):2015-2025. doi: 10.1007/s00296-018-4136-8. Epub 2018 Aug 23. Review.

8.

[Myositis: more than a muscle disease].

Lim J, van Royen-Kerkhof A, Jonkers RE, Starink MV, Voskuyl AE, van der Kooi AJ.

Ned Tijdschr Geneeskd. 2018;162:D2312. Dutch.

PMID:
29473539
9.

[Juvenile idiopathic arthritis].

Schatorjé EJH, van Royen-Kerkhof A.

Ned Tijdschr Tandheelkd. 2018 Feb;125(2):81-86. doi: 10.5177/ntvt.2018.02.17163. Review. Dutch.

PMID:
29461540
10.
11.

Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea".

Mertens JS, de Jong EMGJ, Pandit A, Seyger MMB, Hoppenreijs EPAH, Thurlings RM, Vonk MC, Wienke J, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD.

J Invest Dermatol. 2018 May;138(5):1212-1215. doi: 10.1016/j.jid.2017.11.032. Epub 2017 Dec 12. No abstract available.

PMID:
29246801
12.

Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis.

Blom KJ, Takken T, Huijgen BCH, Wienke J, van Royen-Kerkhof A, van Brussel M.

Rheumatology (Oxford). 2017 Dec 1;56(12):2204-2211. doi: 10.1093/rheumatology/kex366.

PMID:
29029283
13.

Relapsing/remitting type 1 diabetes.

van Megen KM, Spindler MP, Keij FM, Bosch I, Sprangers F, van Royen-Kerkhof A, Nikolic T, Roep BO.

Diabetologia. 2017 Nov;60(11):2252-2255. doi: 10.1007/s00125-017-4403-3. Epub 2017 Aug 23.

14.

Juvenile idiopathic arthritis in a patient with previous diagnosis of severe congenital lupus.

Rotstein Grein IH, Armbrust W, van der Molen AM, van Royen-Kerkhof A.

Lupus. 2018 Jan;27(1):154-157. doi: 10.1177/0961203317709345. Epub 2017 May 18.

PMID:
28649905
15.

Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.

Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov DN, Kim VHD, Ovadia A, Guthery SL, Pulsipher M, Lilic D, Devlin LA, Christie S, Depner M, Fuchs S, van Royen-Kerkhof A, Lindemans C, Petrovic A, Sullivan KE, Bunin N, Kilic SS, Arpaci F, Calle-Martin O, Martinez-Martinez L, Aldave JC, Kobayashi M, Ohkawa T, Imai K, Iguchi A, Roifman CM, Gennery AR, Slatter M, Ochs HD, Morio T, Torgerson TR; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the Primary Immune Deficiency Treatment Consortium.

J Allergy Clin Immunol. 2018 Feb;141(2):704-717.e5. doi: 10.1016/j.jaci.2017.03.049. Epub 2017 Jun 7.

PMID:
28601685
16.

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2018 Jan;77(1):21-29. doi: 10.1136/annrheumdis-2016-210456. Epub 2017 May 15.

17.

The development of offspring from mothers with systemic lupus erythematosus. A systematic review.

Yousef Yengej FA, van Royen-Kerkhof A, Derksen RHWM, Fritsch-Stork RDE.

Autoimmun Rev. 2017 Jul;16(7):701-711. doi: 10.1016/j.autrev.2017.05.005. Epub 2017 May 4. Review.

18.

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4. Review.

PMID:
28473426
19.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):782-791. doi: 10.1136/annrheumdis-2017-211401. Erratum in: Ann Rheum Dis. 2018 Apr;77(4):623.

20.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):911-923. doi: 10.1002/art.40060. Epub 2017 Apr 6. Erratum in: Arthritis Rheumatol. 2018 Mar;70(3):467.

21.

Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review.

Maas A, Braun KP, Geleijns K, Jansen FE, van Royen-Kerkhof A.

Pediatr Neurol. 2017 Jan;66:28-31. doi: 10.1016/j.pediatrneurol.2016.09.002. Epub 2016 Sep 20. Review.

PMID:
27789116
22.

Consensus-based recommendations for the management of juvenile dermatomyositis.

Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A.

Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11. Review.

23.

Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.

Habers GE, Bos GJ, van Royen-Kerkhof A, Lelieveld OT, Armbrust W, Takken T, van Brussel M.

Rheumatology (Oxford). 2016 Jul;55(7):1251-62. doi: 10.1093/rheumatology/kew026. Epub 2016 Mar 27.

PMID:
27018060
24.

Inflammatory mediators in human epilepsy: A systematic review and meta-analysis.

de Vries EE, van den Munckhof B, Braun KP, van Royen-Kerkhof A, de Jager W, Jansen FE.

Neurosci Biobehav Rev. 2016 Apr;63:177-90. doi: 10.1016/j.neubiorev.2016.02.007. Epub 2016 Feb 11. Review.

PMID:
26877106
25.

Serum inflammatory mediators correlate with disease activity in electrical status epilepticus in sleep (ESES) syndrome.

van den Munckhof B, de Vries EE, Braun KP, Boss HM, Willemsen MA, van Royen-Kerkhof A, de Jager W, Jansen FE.

Epilepsia. 2016 Feb;57(2):e45-50. doi: 10.1111/epi.13274. Epub 2015 Dec 14.

26.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

27.

Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy.

van Brussel M, van Oorschot JW, Schmitz JP, Nicolay K, van Royen-Kerkhof A, Takken T, Jeneson JA.

Acad Radiol. 2015 Nov;22(11):1443-8. doi: 10.1016/j.acra.2015.06.013. Epub 2015 Aug 8.

28.

Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.

Compeer EB, Janssen W, van Royen-Kerkhof A, van Gijn M, van Montfrans JM, Boes M.

Oncotarget. 2015 May 10;6(13):10759-71.

29.

Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.

Hampson LV, Whitehead J, Eleftheriou D, Tudur-Smith C, Jones R, Jayne D, Hickey H, Beresford MW, Bracaglia C, Caldas A, Cimaz R, Dehoorne J, Dolezalova P, Friswell M, Jelusic M, Marks SD, Martin N, McMahon AM, Peitz J, van Royen-Kerkhof A, Soylemezoglu O, Brogan PA.

PLoS One. 2015 Mar 30;10(3):e0120981. doi: 10.1371/journal.pone.0120981. eCollection 2015.

30.

Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis.

Habers GE, Van Brussel M, Bhansing KJ, Hoppenreijs EP, Janssen AJ, Van Royen-Kerkhof A, Pillen S.

Muscle Nerve. 2015 Oct;52(4):540-6. doi: 10.1002/mus.24564. Epub 2015 Mar 14.

PMID:
25557638
31.

Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity.

Bellutti Enders F, Delemarre EM, Kuemmerle-Deschner J, van der Torre P, Wulffraat NM, Prakken BP, van Royen-Kerkhof A, van Wijk F.

Ann Rheum Dis. 2015 Jan;74(1):315-7. doi: 10.1136/annrheumdis-2014-206287. Epub 2014 Sep 30. No abstract available.

PMID:
25269830
32.

Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood.

Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H, van Schieveen C, Bakker MH, Klein M, Scholman RC, Spliet W, Ricotti V, Koenen HJ, de Weger RA, Wedderburn LR, van Royen-Kerkhof A, Prakken BJ.

PLoS One. 2014 Aug 26;9(8):e105353. doi: 10.1371/journal.pone.0105353. eCollection 2014.

33.

Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis.

Bellutti Enders F, van Wijk F, Scholman R, Hofer M, Prakken BJ, van Royen-Kerkhof A, de Jager W.

Arthritis Rheumatol. 2014 Aug;66(8):2281-9. doi: 10.1002/art.38676.

34.

Quantitative muscle ultrasound: a potential tool for assessment of disease activity in juvenile dermatomyositis.

Bhansing KJ, Hoppenreijs EP, Janssen AJ, van Royen-Kerkhof A, Nijhuis-Van der Sanden MW, van Riel PL, Pillen S.

Scand J Rheumatol. 2014;43(4):339-41. doi: 10.3109/03009742.2013.879674. Epub 2014 Apr 11. No abstract available.

PMID:
24720507
35.

Overlapping gene expression profiles indicative of antigen processing and the interferon pathway characterize inflammatory fibrotic skin diseases.

Limpers A, van Royen-Kerkhof A, van Roon JA, Radstake TR, Broen JC.

Expert Rev Clin Immunol. 2014 Feb;10(2):231-41. doi: 10.1586/1744666X.2014.872561. Epub 2014 Jan 2. Review.

PMID:
24382112
36.

Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?

van Royen-Kerkhof A, Vastert BS, Swart JF, Wulffraat NM.

Immunotherapy. 2014;6(1):1-3. doi: 10.2217/imt.13.153. No abstract available.

37.
38.

Expression of CD64 (FcγRI) in skin of patients with acute GVHD.

van Royen-Kerkhof A, Walraven V, Sanders EA, de Weger R, van Wichen DF, de Koning E, Thepen T, van de Winkel JG, Leusen JH.

Bone Marrow Transplant. 2011 Dec;46(12):1566-9. doi: 10.1038/bmt.2010.337. Epub 2011 Jan 17.

PMID:
21243031
39.

Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis.

Holzer U, van Royen-Kerkhof A, van der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R, Mueller I, Wulffraat N.

Scand J Rheumatol. 2010;39(1):88-92. doi: 10.3109/03009740903096622.

PMID:
20132077
40.

Treatment of refractory juvenile dermatomyositis with tacrolimus.

Hassan J, van der Net JJ, van Royen-Kerkhof A.

Clin Rheumatol. 2008 Nov;27(11):1469-71. doi: 10.1007/s10067-008-0973-2. Epub 2008 Aug 21.

PMID:
18716733
41.

Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix Gla protein.

van Summeren MJ, Spliet WG, van Royen-Kerkhof A, Vermeer C, Lilien M, Kuis W, Schurgers LJ.

Rheumatology (Oxford). 2008 Mar;47(3):267-71. doi: 10.1093/rheumatology/kem360. Epub 2008 Jan 29.

PMID:
18234711
42.

[The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].

Hoogendijk JE, Bijlsma JW, van Engelen BG, Lindeman E, van Royen-Kerkhof A, de Rie MA, de Visser M, Jennekens FG; werkgroep Myositis.

Ned Tijdschr Geneeskd. 2005 Sep 17;149(38):2104-11. Dutch.

PMID:
16201600
43.

A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice.

van Royen-Kerkhof A, Sanders EA, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, Gerritsen A, van Dijk MA, Kuis W, Rijkers GT, Vitale L, Keler T, McKenzie SE, Leusen JH, van de Winkel JG.

Br J Haematol. 2005 Jul;130(1):130-7.

PMID:
15982355
44.

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.

Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C.

Genet Med. 2005 Feb;7(2):143-6.

PMID:
15714083
45.

Flow cytometric determination of FcgammaRIIa (CD32) polymorphism.

van Royen-Kerkhof A, Sanders EA, Wijngaarden S, van Roon JA, Voorhorst-Ogink M, Walraven V, Gerritsen A, van Dijk MA, Kuis W, Rijkers GT, Keler T, Leusen JH, van de Winkel JG.

J Immunol Methods. 2004 Nov;294(1-2):135-44. Epub 2004 Oct 6.

PMID:
15604023
46.

Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patient.

van Royen-Kerkhof A, Wulffraat NM, Kamphuis SS, Brooimans RA, de Weger RA, Tilanus MG, van Leeuwen EF, Rijkers GT.

Bone Marrow Transplant. 2003 Nov;32(10):1027-30.

PMID:
14595391
47.

Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome.

Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, Frenkel J, Dorland L, de Barse MM, Huijbers WA, Rijkers GT, Waterham HR, Wanders RJ, Poll-The BT.

Nat Genet. 1999 Jun;22(2):175-7.

PMID:
10369261
48.

Coexistence of Gaucher disease type 1 and Joubert syndrome.

van Royen-Kerkhof A, Poll-The BT, Kleijer WJ, van Diggelen OP, Aerts JM, Hopwood JJ, Beemer FA.

J Med Genet. 1998 Nov;35(11):965-6. No abstract available.

Supplemental Content

Loading ...
Support Center